A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate MRG003 vs Cetuximab/Methotrexate as Second/Third Line of Treatment in Patient With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
Latest Information Update: 08 Mar 2023
At a glance
- Drugs MRG 003 (Primary) ; Cetuximab; Methotrexate
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Miracogen
Most Recent Events
- 08 Mar 2023 New trial record